BioMarin Pharmaceutical's total assets for Q1 2026 were $8.59B, an increase of 13.13% from the previous quarter. BMRN total liabilities were $2.38B for the fiscal quarter, a 57.85% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.